Displaying 1 - 28 of 28 results
Released Company Title Industry Topic
17 Oct 2024
08:50 CEST
BenevolentAI BenevolentAI Appoints Kenneth Mulvany as Executive Chairman 20103010 Biotechnology Other subject
19 Sep 2024
07:00 CEST
BenevolentAI BenevolentAI Interim Results for the Six Months Ended 30 June 2024 20103010 Biotechnology Commercial operations
03 Jul 2024
07:00 CEST
BenevolentAI BenevolentAI: Leadership Team Change 20103010 Biotechnology Other subject
02 May 2024
15:30 CEST
BenevolentAI BenevolentAI: Result of Annual General Meeting 20103010 Biotechnology General meeting / Board Meeting
23 Apr 2024
07:00 CEST
BenevolentAI BenevolentAI Provides an Update on Its Business Priorities 20103010 Biotechnology Commercial operations
17 Apr 2024
07:00 CEST
BenevolentAI BenevolentAI: Publication of the Revised Agenda for the 2024 AGM 20103010 Biotechnology General meeting / Board Meeting
15 Apr 2024
07:00 CEST
BenevolentAI Proposed Changes to BenevolentAI’s Board Composition 20103010 Biotechnology Journal / appointments
25 Mar 2024
07:00 CET
BenevolentAI BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers 20103010 Biotechnology Commercial operations
20 Mar 2024
07:00 CET
BenevolentAI BenevolentAI: Publication of 2023 Annual Report and 2024 AGM Notice 20103010 Biotechnology General meeting / Board Meeting
14 Mar 2024
07:00 CET
BenevolentAI BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023 20103010 Biotechnology Commercial operations
24 Jan 2024
07:00 CET
BenevolentAI BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer 20103010 Biotechnology Journal / appointments
28 Dec 2023
07:00 CET
BenevolentAI BenevolentAI:Shareholder Letter December 2023 20103010 Biotechnology Other subject
21 Sep 2023
07:01 CEST
BenevolentAI BenevolentAI: Interim Results for the Six Months Ended 30 June 2023 20103010 Biotechnology Other subject
21 Sep 2023
07:00 CEST
BenevolentAI BenevolentAI: Directorate Change 20103010 Biotechnology Journal / appointments
20 Sep 2023
07:00 CEST
BenevolentAI BenevolentAI Signs Strategic Collaboration with Merck 20103010 Biotechnology Other subject
18 Sep 2023
07:00 CEST
BenevolentAI BenevolentAI Welcomes Christina Busmalis as its New Chief Revenue Officer 20103010 Biotechnology Journal / appointments
15 Sep 2023
07:00 CEST
BenevolentAI BenevolentAI Notice of Interim Results 20103010 Biotechnology Other subject
11 Sep 2023
07:00 CEST
BenevolentAI BenevolentAI: Appointment of Catherine Isted, ACMA, as Chief Financial Officer 20103010 Biotechnology Journal / appointments
31 Aug 2023
07:00 CEST
BenevolentAI BenevolentAI Doses First Participants in Clinical Trial of BEN-8744; Targets PDE10, an AI-derived Novel Target for the Treatment of Ulcerative Colitis 20103010 Biotechnology New
21 Jun 2023
07:00 CEST
BenevolentAI BenevolentAI: Board Change 20103010 Biotechnology Journal / appointments
25 May 2023
07:00 CEST
BenevolentAI BenevolentAI Unveils Strategic Plan to Position the Company for a New Era in AI 20103010 Biotechnology Other subject
05 Apr 2023
07:00 CEST
BenevolentAI BenevolentAI Announces Top-Line Phase IIa Results for Its Topical pan-Trk Inhibitor BEN-2293 (1%) in Mild-to-Moderate Atopic Dermatitis 20103010 Biotechnology New
24 Mar 2023
07:00 CET
BenevolentAI BenevolentAI Announces Publication of Convening Notice for AGM 20103010 Biotechnology General meeting / Board Meeting
22 Mar 2023
07:00 CET
BenevolentAI BenevolentAI Strengthens its Board of Directors with the Appointment of Digital Innovation Expert Marcello Damiani 20103010 Biotechnology New
16 Mar 2023
07:00 CET
BenevolentAI BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022 20103010 Biotechnology Income
06 Oct 2022
07:00 CEST
BenevolentAI BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca 20103010 Biotechnology New
27 Sep 2022
14:55 CEST
BenevolentAI BenevolentAI Analyst / Investor Event 20103010 Biotechnology Meetings / events
27 Sep 2022
07:00 CEST
BenevolentAI BenevolentAI Interim Results for the Six Months Ended 30 June 2022 20103010 Biotechnology Income